Pathology

Pramana Joins Proscia Ready To Help Laboratories Realize More Value From Their Pathology Data

Retrieved on: 
Tuesday, February 27, 2024
USCAP, Marie Cassidy, Freedom, Traction, Pathology, Metadata, Organization, DICOM, Laboratory, Research, Partnership, Medical imaging

and PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Proscia® , a leading provider of digital and computational pathology solutions, today announced that Pramana, Inc. , an AI-enabled health tech company modernizing the pathology sector, is now a Proscia Ready partner.

Key Points: 
  • and PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Proscia® , a leading provider of digital and computational pathology solutions, today announced that Pramana, Inc. , an AI-enabled health tech company modernizing the pathology sector, is now a Proscia Ready partner.
  • Pramana joins the partner alliance to help life sciences organizations and diagnostic laboratories increasingly leverage enriched, high-quality data, including DICOM images, in their routine research and clinical operations.
  • Proscia Ready was established to help laboratories accelerate the scaled adoption of digital pathology with confidence.
  • To learn more, visit Proscia at booth 200 and Pramana at booth 549 during the upcoming United States and Canadian Academy of Pathology (USCAP) 113th Annual Meeting.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024
ACT, ERP, Central nervous system, Dementia, Excitotoxicity, ALS, Research, MNDA, Pathology, Research and development, Inflammation, HGF, Conference, Society, Annual general meeting, Doctor of Philosophy, Frontiers, Biomarker, Administration, Clinical trial, Survival, Investment, Neuroprotection, Three-body problem, G&A, Athira Pharma, Lewy body, Insurance, Pharmaceutical industry

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

Retrieved on: 
Wednesday, February 21, 2024
ABOS, Immunotherapy, Pathology, Neurogranin, USAN, Conference, Safety, Biomarker, DSM-IV codes, Pharmaceutical industry

CHARLOTTESVILLE, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will be presenting biomarker data and target engagement methods in an oral and poster presentation, respectively, at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD), taking place March 5-9, 2024, in Lisbon, Portugal, and online.

Key Points: 
  • Acumen’s sabirnetug (ACU193) is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs, a soluble and highly toxic form of Aβ that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration.
  • Positive topline results from 62 participants in the Phase 1 INTERCEPT-AD trial (NCT04931459) showed sabirnetug to be well-tolerated with a favorable overall safety profile.
  • Effects of sabirnetug on both neurogranin and pTau181 levels in CSF in this Phase 1 study are consistent with downstream pharmacologic effects of the drug.
  • Presentation details as follows:
    Sabirnetug is the nonproprietary name for ACU193 accepted by USAN and INN.

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Software, General Health, Science, Data Management, Clinical Trials, Community health, GSK, AbbVie, Huntington's disease, University, Mathematics, Emory University, Behavioral neurology, Pathology, School, Alzheimer's disease, Johnson & Johnson, Drug design, Gold, Bristol Myers Squibb, Johns Hopkins, Disorder, Psychiatry, Derek, UCB, Computer science, American Neurological Association, Asha, Parkinson's Foundation, Conference, Chemistry, Safety, Amelioration, CNS, Behavioural sciences, Medical school, MD, Neurology, Patient, Florida College, Disease, Publication, DRS, Pharmaceutical industry

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial

Retrieved on: 
Thursday, March 7, 2024
Mental Health, Neurology, Clinical Trials, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Blood, Natural history, University, Alzheimer's disease, Multimedia, Research, Pathology, News, ADAS, Conference, AFL, Patient, Disease, Psychiatry, ADNI, Dementia, MRI, Brain, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240307066794/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307066794/en/
    New 24-month data show sustained benefits across the disease spectrum from early to moderate dementia.
  • Analyses comparing the study participants to closely matched real world data and meta-analytical controls, showed significantly reduced disease progression in participants in the LUCIDITY trial.
  • In the early disease subgroup there was a significant reduction in transition to the dementia stage of AD.
  • Its secondary pharmacological action is symptomatic through increasing acetylcholine levels in parts of the brain essential for memory functions.

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Retrieved on: 
Wednesday, March 6, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Central nervous system, Investigational New Drug, Houston Methodist Hospital, Chemokine, Frontotemporal dementia, Messenger, FDA, COYA, Conference, FTD, Therapy, Pathology, Patient, Poster, Role, IND, Pharmaceutical industry

The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .

Key Points: 
  • The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .
  • We intend to file an Investigational New Drug (IND) application with the FDA for COYA 302 in FTD later this year and initiate a Ph.
  • 2 trial in FTD patients shortly thereafter,” stated Fred Grossman, Chief Medical Officer at Coya Therapeutics.
  • In addition, several inflammation transcripts in monocyte genes known to be involved in neuroinflammatory signaling pathways were dysregulated in FTD, compared to controls.

Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Technology, FDA, Health, Pharmaceutical, Oncology, Other Science, Research, Artificial Intelligence, Science, Clinical Trials, NSCLC, Cancer, Clonal hematopoiesis, Doctor of Philosophy, Artificial intelligence, Immunotherapy, Neoplasm, Pathology, TME, PCG, Effectiveness, AACR, Interface, Data, HER2, Lung cancer, Genentech, Flatiron, Roche, Biomarker, Tumor microenvironment, Abstract, Patient, Survival, Foundation Medicine, Plasma, DNA, Medical imaging

Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.

Key Points: 
  • Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.
  • ​Results suggest ​serial early ctDNA monitoring ​is a valuable complementary tool for real-time treatment response monitoring to targeted therapy.
  • These findings may enable personalized therapy approaches tailored to a patient’s risk of progression and downstream cancer treatment planning.
  • Follow Foundation Medicine on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #3117.

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Health Technology, Senior, Pathology, Eisai, Growth, Deficit spending, History, Patient, Dementia, CSF, Diagnosis, PET, Medical imaging

C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

Key Points: 
  • C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
  • C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests , which are innovative blood tests intended for use in patients with cognitive impairment.
  • These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
  • “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth.

Telios Pharma Announces Successful Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Disease

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, BTK, Senior, ARVO, Research, MD, Inflammation, Pathology, Telecanthus, Pharma, Allergic conjunctivitis, Annual general meeting, Safety, DED, Patient, AC, Pharmaceutical industry

TL-925 was safe and well tolerated and the intention-to-treat analysis demonstrated clinically meaningful and statistically significant efficacy relative to vehicle control across multiple signs and symptoms.

Key Points: 
  • TL-925 was safe and well tolerated and the intention-to-treat analysis demonstrated clinically meaningful and statistically significant efficacy relative to vehicle control across multiple signs and symptoms.
  • “The results are among the most impressive that I have seen in my years working on dry eye clinical development programs.
  • TL-925 is a promising and much needed novel approach for the treatment of DED.”
    A Phase 2b study of TL-925 in DED has been initiated based on these results and is currently enrolling patients.
  • It is increasingly apparent that TL-925 may represent a significant leap forward for the effective treatment of DED and AC.”

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Retrieved on: 
Monday, March 4, 2024
Research, General Health, Pharmaceutical, Biometrics, Consumer, Clinical Trials, Science, Biotechnology, Neurology, Seniors, FDA, Health, Alzheimer's disease, Pathology, PET, Cerebrospinal fluid, Food, Breakthrough, Risk, Simoa, Biomarker, Deficit spending, Patient, CSF, Diagnosis, Plasma, Corporation, Medical device

The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.

Key Points: 
  • The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.
  • The Simoa p-Tau 217 test described in the Breakthrough Device application is a semi-quantitative in vitro diagnostic immunoassay intended for the measurement of p-Tau 217 concentration in plasma using the Quanterix HD-X immunoassay system.
  • The Breakthrough Device designation for the p-Tau 217 test underscores its potential to significantly impact Alzheimer's disease (AD) diagnosis and treatment.
  • However, Breakthrough Device designation does not guarantee that the FDA review and approval process will be shortened or that an application will be approved.